NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a note issued to investors on Friday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

Shares of NURO stock opened at $4.31 on Friday. The stock’s fifty day simple moving average is $4.09 and its 200 day simple moving average is $3.84. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73. The firm has a market cap of $8.79 million, a price-to-earnings ratio of -0.94 and a beta of 2.18.

NeuroMetrix (NASDAQ:NURO) last issued its earnings results on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. The firm had revenue of $0.59 million during the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. During the same quarter in the previous year, the company earned ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.